What is the 13F Pro Quality Score for XOMA?

13F Pro ranks XOMA Royalty Corp (XOMA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XOMA's current score at https://13fpro.ai/company/XOMA (free sign-up required for the full ranking).

Which hedge funds own the most XOMA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XOMA include BVF /IL, MORGAN STANLEY, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/XOMA as soon as new 13F filings post.

Where does 13F Pro source XOMA data?

All XOMA Royalty Corp fundamentals and ownership data come directly from SEC EDGAR. XOMA Royalty Corp files with the SEC under CIK 791908. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XOMA in?

XOMA Royalty Corp (XOMA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives XOMA's revenue?

Per XOMA Royalty Corp's latest 10-Q filed with the SEC on 2026-05-12, the biggest revenue drivers are: Income from purchased receivables under the EIR method ($9.2M, +52% YoY); Affitech (VABYSMO) ($6.7M, +15% YoY); LadRx (MIPLYFFA) ($2.3M). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/XOMA.

What are XOMA's largest expenses?

XOMA Royalty Corp's latest 10-Q reports these as the largest expense items: General and administrative ($11.9M, +46% YoY); Amortization of intangible assets ($892K, +64% YoY); Research and development ($49K, -96% YoY). Sourced directly from SEC EDGAR filing text for Q1 FY2026 (quarter ended March 31, 2026).

How often is XOMA research updated on 13F Pro?

XOMA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

XOMA Royalty Corp(XOMA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 791908 XOMA stock profile & AI dashboard →

13F Pro Quality Score

69.7/100

Rank #250 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

98.4/100

Profitability

99.1/100

Balance Sheet

91.7/100

Earnings Quality

51.1/100

Free Cash Flow

63.8/100

Institutional Flow

99.2/100

Revenue Scale

8.5/100

Dilution Risk

10.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why XOMA Scores 68/100

exact factor attribution · 2026-08-29

XOMA's composite is driven by revenue growth and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.3 pts

97th pct

Profitability

+6.9 pts

96th pct

Free cash flow

+5.1 pts

84th pct

Capital efficiency

+4.0 pts

90th pct

Institutional flow

+2.3 pts

96th pct

Earnings quality

+0.1 pts

51th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-2.0 pts

10th pct

Scale

-6.6 pts

6th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

XOMA Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for XOMA Royalty Corp (XOMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XOMA at 69.7/100 on a 32-signal composite quality model, placing it at rank #250 of 2,961 stocks — the top 10% of the AI-ranked universe. XOMA scores in the top quartile across institutional flow (99.2), profitability (99.1), revenue growth (98.4). Areas of concern include revenue scale (8.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), XOMA Royalty Corp reports quarterly revenue of $12.3M, net income of $4.5M. Top institutional holders of XOMA by reported 13-F value include BVF, MORGAN STANLEY, FMR, based on the most recent SEC filings. XOMA trades on the Nasdaq exchange and files with the SEC under CIK 791908. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XOMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for XOMA Royalty Corp directly from SEC EDGAR. XOMA Royalty Corp's 13F Pro composite quality score has ranged between 10 and 70 since 2024, currently 69.7 — an improving long-term trajectory across 54 quarterly and live scoring snapshots.

✦

Fun facts about XOMA Royalty Corp

Quirks, history, and lore behind XOMA — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap healthcare company listed on Nasdaq, headquartered in Northern California, that holds royalty interests rather than developing drugs itself.
2
The Numbers
Revenue is modest — think tens of millions annually — because the model is purely passive income: collect a cut when others sell, and sit back.
3
The History
The company has roots going back to the 1980s biotech boom and spent decades as a conventional drug developer before pivoting to a pure royalty model in the 2010s.
4
The Secret
It doesn't run labs, hire scientists, or conduct clinical trials — it acquires royalty rights on FDA-approved or late-stage drugs and lets larger pharma companies do all the heavy lifting.
5
The Lore
Think of it as the landlord of biotech: it owns a portfolio of milestone and royalty rights spread across multiple therapeutic areas, clipping coupons every time a partnered drug sells.
6
The Giveaway
Its four-letter ticker doubles as a surname, its business is literally biotech royalties, and it trades on Nasdaq under a name that sounds like a European monarch crossed with a biopharma.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving XOMA's Business? Latest 10-Q Breakdown

✓ 23/23 datapoints verified

AI-extracted from XOMA Royalty Corp's 10-Q filed 2026-05-12 — Q1 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

XOMA's total income and revenues fell 23% YoY to $12.3M as a prior-year $4.0M Takeda milestone did not repeat, while the company agreed to be acquired by Ligand for $39.00/share (~$739M equity value) announced April 27, 2026.

Biggest Revenue Drivers

Income from purchased receivables under the EIR method$9.2M+52% YoY

Higher estimated income from VABYSMO, plus newly reliably-estimable MIPLYFFA cash flows

Income from purchased receivables under the cost recovery method$2.8M-50% YoY

Prior year included a $4.0M Day One MAA-filing milestone plus royalties; this quarter reflects OJEMDA royalties only

Biggest Revenue Drivers

Total revenue: $12.3M-23% YoY

Income from purchased receivables under the EIR method$9.2M+52% YoY

Higher estimated income from VABYSMO, plus newly reliably-estimable MIPLYFFA cash flows

Within Income from purchased receivables under the EIR method

Affitech (VABYSMO)$6.7M+15% YoY

Roche VABYSMO commercial payments under the Affitech CPPA

LadRx (MIPLYFFA)$2.3M

Reclassified to EIR method in Q4 2025 once Zevra sales data allowed reliable cash-flow estimation

Income from purchased receivables under the cost recovery method$2.8M-50% YoY

Prior year included a $4.0M Day One MAA-filing milestone plus royalties; this quarter reflects OJEMDA royalties only

Revenue from contracts with customers$0-100% YoY

Prior-year quarter included a $4.0M payment under the Takeda Collaboration Agreement that did not recur

Largest Expense Items

General and administrative$11.9M+46% YoY

Increases in salaries, lease expense, tax services, legal fees, stock-based compensation, and litigation costs from the Janssen lawsuit

Amortization of intangible assets$892K+64% YoY

Amortization of Pulmokine/seralutinib and BioInvent contract-based intangible assets

Research and development$49K-96% YoY

Prior year included pass-through licensing fees tied to a Takeda milestone and Kinnate KIN-3248 wind-down costs

Margins: The company swung from operating income of $5.9M in Q1 2025 to an operating loss of $0.5M in Q1 2026, as lower milestone/contract revenue combined with higher G&A (litigation, lease, tax and legal costs) outpaced growth in EIR-method royalty income.

Watch Items from the Filing

Three partners represented 54%, 22% and 19% of total income and revenues for the quarter, indicating high revenue concentration.
XOMA agreed to be acquired by Ligand for $39.00/share in cash (~$739.0M equity value) plus a CVR; deal expected to close Q3 2026 subject to stockholder and regulatory approval, with a $40.0M termination fee in specified circumstances.
Two portfolio Phase 3 assets recently missed endpoints: Rezolute's ersodetug (Dec 2025) and Gossamer Bio's seralutinib PROSERA trial (Feb 2026), though no impairment was recorded on related XOMA assets.
Merger CVR value depends entirely on the outcome of ongoing Janssen litigation over TREMFYA, which is still in early discovery; the CVR could expire worthless.
Revenue from contracts with customers dropped to zero from $4.0M a year ago, highlighting the lumpy, milestone-dependent nature of that revenue line.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$12.3M

Net Income

Q1 2026

$4.5M

ROIC

Q1 2026

-1.0%

D/E Ratio

Q1 2026

1.11

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+83.1% YoY

$52.1MFY 2025

FY22 $6.0MFY23 $4.8MFY24 $28.5MFY25 $52.1M

Net Income

+329.4% YoY

$31.7MFY 2025

FY22 $-17.1MFY23 $-40.8MFY24 $-13.8MFY25 $31.7M

Operating Income

+128.5% YoY

$11.4MFY 2025

FY22 $-17.4MFY23 $-41.8MFY24 $-40.0MFY25 $11.4M

EPS (Diluted)

+188.5% YoY

$1.46FY 2025

FY22 $-1.98FY23 $-4.04FY24 $-1.65FY25 $1.46

Total Assets

+23.2% YoY

$272.7MFY 2025

FY22 $140.4MFY23 $234.3MFY24 $221.3MFY25 $272.7M

Total Debt

-7.9% YoY

$109.0MFY 2025

FY22 $0.00FY23 $124.1MFY24 $118.3MFY25 $109.0M

Op. Cash Flow

+120.9% YoY

$2.9MFY 2025

FY22 $-12.9MFY23 $-18.2MFY24 $-13.7MFY25 $2.9M

Free Cash Flow

—FY 2025

FY22 $-28.1MFY23 $-18.2MFY24 $-13.8MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$52.1M +83.1%	$28.5M +498.7%	$4.8M -21.1%	$6.0M -84.2%	$38.2M +29.9%	$29.4M
Net Income	$31.7M +329.4%	$-13.8M +66.2%	$-40.8M -138.7%	$-17.1M -208.3%	$15.8M +18.8%	$13.3M
Operating Income	$11.4M +128.5%	$-40.0M +4.5%	$-41.8M -140.3%	$-17.4M -199.3%	$17.5M +41.2%	$12.4M
EPS (Diluted)	$1.46 +188.5%	$-1.65 +59.2%	$-4.04 -104.0%	$-1.98 -404.6%	$0.65 -16.7%	$0.78
Total Assets	$272.7M +23.2%	$221.3M -5.6%	$234.3M +66.9%	$140.4M -15.7%	$166.6M +32.9%	$125.3M
Total Debt	$109.0M -7.9%	$118.3M -4.7%	$124.1M	$0.00	—	$28.9M
Operating Cash Flow	$2.9M +120.9%	$-13.7M +24.3%	$-18.2M -41.0%	$-12.9M -156.8%	$22.7M +124.7%	$10.1M
Free Cash Flow	—	$-13.8M +24.2%	$-18.2M +35.4%	$-28.1M	—	$10.1M

Get alerted when XOMA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for XOMA Royalty Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XOMA

BVF INC/IL
$322.7M7,593,303 sh
MORGAN STANLEY
$72.1M1,697,167 sh
FMR LLC
$68.2M1,605,532 sh
Woodline Partners LP
$47.4M1,114,363 sh
Newtyn Management, LLC
$30.1M709,247 sh
BlackRock, Inc.
$29.4M691,971 sh
VANGUARD CAPITAL MANAGEMENT LLC
$21.5M505,165 sh
Opaleye Management Inc.
$14.4M338,374 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.4M245,321 sh
WATER ISLAND CAPITAL LLC
$10.3M242,000 sh

Fund	Value	Shares
BVF INC/IL	$322.7M	7,593,303
MORGAN STANLEY	$72.1M	1,697,167
FMR LLC	$68.2M	1,605,532
Woodline Partners LP	$47.4M	1,114,363
Newtyn Management, LLC	$30.1M	709,247
BlackRock, Inc.	$29.4M	691,971
VANGUARD CAPITAL MANAGEMENT LLC	$21.5M	505,165
Opaleye Management Inc.	$14.4M	338,374
GEODE CAPITAL MANAGEMENT, LLC	$10.4M	245,321
WATER ISLAND CAPITAL LLC	$10.3M	242,000

Companies Similar to XOMA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

FBIO

Fortress Biotech, Inc.

AI score

Similar quality profile · 1 shared holders

Opaleye Management Inc.

LQDA

Liquidia Corp

AI score

Similar quality profile · 1 shared holders

Opaleye Management Inc.

ETON

Eton Pharmaceuticals, Inc.

AI score

Similar quality profile · 1 shared holders

Opaleye Management Inc.

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile · 1 shared holders

MARTINGALE ASSET MANAGEMENT L P

AUPH

Aurinia Pharmaceuticals Inc.

AI score

Similar quality profile · 1 shared holders

MARTINGALE ASSET MANAGEMENT L P

IRMD

IRADIMED CORP

AI score

Similar quality profile · 1 shared holders

MARTINGALE ASSET MANAGEMENT L P

TBPH

Theravance Biopharma, Inc.

AI score

Similar quality profile · 3 shared holders

Newtyn Management, LLC SIERRA SUMMIT ADVISORS LLC MARTINGALE ASSET MANAGEMENT L P

BLLN

BillionToOne, Inc.

AI score

Similar quality profile · 1 shared holders

SIERRA SUMMIT ADVISORS LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XOMA on your watchlist

Track score changes the day XOMA Royalty Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XOMA a good stock to buy?

13F Pro's AI-powered analysis of XOMA Royalty Corp (XOMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XOMA are available on the XOMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. XOMA is classified as a small company.

Which hedge funds own XOMA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XOMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of XOMA Royalty Corp's investment landscape.